Notice of Results
genedrive plc
("genedrive" or the "Company")
Notice of Results
Investor Presentation
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2021 on Tuesday, 29 March 2022.
The Company will provide a live presentation to accompany the interim results, presented by CEO, David Budd and CFO, Matthew Fowler on Thursday, 31 March 2022 at 10.00am.
The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet genedrive plc via the following link: https://www.investormeetcompany.com/genedrive-plc/register-investor
For further details please contact:
|
genedrive plc |
+44 (0)161 989 0245 |
|
David Budd: CEO / Matthew Fowler: CFO |
|
|
|
|
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+44 (0)20 7418 8900 |
|
James Steel |
|
|
|
|
|
finnCap (Joint Broker) |
+44 (0)20 7220 0500 |
|
Geoff Nash / Kate Bannatyne / Alice Lane |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
+44 (0)20 7933 8780 or genedrive@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
+44 (0)7980 541 893 / +44 (0)7876 741 001 |
About genedrive plc ( http://www.genedriveplc.com ) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and a test to help in the prevention of hearing loss caused by certain antibiotics in neonates. The Company recently released point of care test for Covid-19.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
COMPANIES COVERED:
Latest directors dealings
- 8 hours ago Argentex Group
- 9 hours ago Centrica
- 10 hours ago OSB Group
- 10 hours ago Legal & General Group
- 10 hours ago Team17 Group